TrialBMC medicine2025

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.

Shuyu Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.